GSK159797

GlaxoSmithKline · Phase 2 active Small molecule

At a glance

Generic name	GSK159797
Sponsor	GlaxoSmithKline
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic Patients (PHASE2)
Single Doses GSK159797 On Patient Safety And Lung Function In Patients With Mild To Moderate Asthma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GSK159797 CI brief — competitive landscape report
GSK159797 updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI